Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
296.24B
Market cap296.24B
Price-Earnings ratio
16.46
Price-Earnings ratio16.46
Dividend yield
2.74%
Dividend yield2.74%
Average volume
10.42M
Average volume10.42M
High today
$122.96
High today$122.96
Low today
$118.61
Low today$118.61
Open price
$119.36
Open price$119.36
Volume
9.33M
Volume9.33M
52 Week high
$125.14
52 Week high$125.14
52 Week low
$73.31
52 Week low$73.31

Stock Snapshot

The current Merck(MRK) stock price is $119.59, with a market capitalization of 296.24B. The stock trades at a price-to-earnings (P/E) ratio of 16.46 and offers a dividend yield of 2.7%.

On 2026-03-04, Merck(MRK) stock moved within a range of $118.61 to $122.96. With shares now at $119.59, the stock is trading +0.8% above its intraday low and -2.7% below the session's peak.

Trading volume for Merck(MRK) stock has reached 9.33M, versus its average volume of 10.42M.

Over the past 52 weeks, Merck(MRK) stock has traded between a high of $125.14 and a low of $73.31.

Over the past 52 weeks, Merck(MRK) stock has traded between a high of $125.14 and a low of $73.31.

MRK News

Benzinga 15h
AI-Powered Tempus Inks New Multi-Year Merck Deal

Tempus AI Inc. (NASDAQ:TEM) on Tuesday inked a strategic collaboration agreement with Merck & Co. Inc. (NYSE:MRK) aimed at accelerating AI-driven precision medi...

AI-Powered Tempus Inks New Multi-Year Merck Deal
24/7 Wall St. 17h
Most Retirees Overlook These Dow Dividend Stocks — They Pay More Than You'd Expect

Most Retirees Overlook These Dow Dividend Stocks — They Pay More Than You’d Expect Quick Read Chevron (CVX) up 83% over 25 years, Home Depot (HD) up 42% in 5 y...

Most Retirees Overlook These Dow Dividend Stocks — They Pay More Than You'd Expect
Simply Wall St 17h
Merck’s Oncology Results And Tempus AI Deal Reframe Post Keytruda Future

Merck (NYSE:MRK) reported positive Phase 3 results for KEYTRUDA combinations in renal cell carcinoma, ovarian cancer, and bladder cancer. The company also secu...

Merck’s Oncology Results And Tempus AI Deal Reframe Post Keytruda Future

Analyst ratings

61%

of 31 ratings
Buy
61.3%
Hold
38.7%
Sell
0%

More MRK News

TipRanks 21h
Tempus AI, Merck announce AI-driven precision medicine collaboration

Tempus AI (TEM) and Merck (MRK) announced an expanded, multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomar...

Nasdaq 1d
Merck Stock Dips While Market Gains: Key Facts

Merck (MRK) closed the most recent trading day at $117.23, moving -1.19% from the previous trading session. This change lagged the S&P 500's 1.7% gain on the da...

Merck Stock Dips While Market Gains: Key Facts
TipRanks 2d
Exelixis price target lowered to $43 from $46 at RBC Capital

RBC Capital lowered the firm’s price target on Exelixis (EXEL) to $43 from $46 and keeps a Sector Perform rating on the shares. The firm notes that competitive...

TipRanks 3d
Merck, Eisai announce results on Phase 3 Litespark-011 trial of Welireg

Merck (MRK), known as MSD outside of the United States and Canada, and Eisai (ESAIY) announced the first presentation of results from the Phase 3 LITESPARK-011...

Simply Wall St 4d
Should Merck’s New STK-012 Keytruda Lung Cancer Combo Strategy Require Action From Investors?

In late February 2026, Synthekine announced a collaboration and supply agreement with Merck to test STK-012 alongside Keytruda and chemotherapy in the ongoing g...

Should Merck’s New STK-012 Keytruda Lung Cancer Combo Strategy Require Action From Investors?
Investor's Business Daily 5d
Merck Stock, Up 13% In 2026, Ticks Another Box. Is It Now A Buy?

Technology Merck Stock, Up 13% In 2026, Ticks Another Box. Is It Now A Buy? Licensing Merck (MRK) stock, which has climbed 13% in 2026, ticked another box Frida...

Merck Stock, Up 13% In 2026, Ticks Another Box. Is It Now A Buy?
TipRanks 5d
Merck announces results of final analysis of Phase 3 KEYNOTE-B96 trial

Merck (MRK) announced results from the final analysis of the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, showing that KEYTRUDA, Merck’s anti-PD...

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.